The reported loss was better than expected. Celldex posted a second-quarter loss of $0.94 per share versus published estimates clustered around roughly $1.06–$1.20, a meaningful but relatively low-quality beat because the company has essentially no product revenue.
| $ millions, except per-share data | Q2 2026 | Q2 2025 | Six months 2026 | Six months 2025 |
|---|---|---|---|---|
| Total revenues | $0.02 *(Consolidated Statements of Operations)* | $0.73 *(Consolidated Statements of Operations)* | $0.04 *(Consolidated Statements of Operations)* | $1.42 *(Consolidated Statements of Operations)* |
| R&D expense | $67.5 *(R&D Expenses)* | $54.2 *(R&D Expenses)* | $140.5 *(R&D Expenses)* | $106.8 *(R&D Expenses)* |
| G&A expense | $13.1 *(G&A Expenses)* | $10.4 *(G&A Expenses)* | $24.6 *(G&A Expenses)* | $21.2 *(G&A Expenses)* |
| Net loss | $(73.5) *(Net Loss)* | $(56.6) *(Net Loss)* | $(152.2) *(Net Loss)* | $(110.4) *(Net Loss)* |
| Net loss per share | $(0.94) *(Net Loss)* | $(0.85) *(Net Loss)* | $(2.11) *(Net Loss)* | $(1.66) *(Net Loss)* |
| Cash, cash equivalents and marketable securities | $717.6 *(Cash Position)* | — | — | — |
The balance sheet is the more important financial takeaway. Cash reached $717.6 million at June 30, up from $451.5 million at March 31 after the April offering generated $323.8 million of net proceeds; second-quarter operating cash burn was $57.4 million *(Cash Position)*. Management says that funds current planned operations through 2028 *(Financial Guidance)*, reducing near-term financing pressure but not changing the long-term dependence on barzolvolimab clinical success.
Spending is rising as the pivotal program advances. R&D increased 25% year over year to $67.5 million, driven by barzolvolimab trials, manufacturing and headcount, while G&A rose 26% to $13.1 million as commercial planning began *(R&D Expenses; G&A Expenses)*. That is consistent with an advancing late-stage program, but it also explains why the earnings beat should not be treated as improved underlying economics.
The clinical update mostly confirms the roadmap rather than creating a new catalyst. Enrollment in the two Phase 3 chronic spontaneous urticaria studies finished six months ahead of guidance, with topline data still expected in September or October 2026 and a planned 2027 BLA filing *(Recent Program Highlights — Chronic Urticarias)*. The timing is constructive, but the data window was already expected; the filing does not provide efficacy results. The negative Phase 2 prurigo nodularis result and study discontinuation were also already disclosed in July *(Recent Program Highlights — Atopic Dermatitis and Prurigo Nodularis)*.
Net: modestly better financially, but the investment case remains centered on the upcoming Phase 3 readout. The EPS beat and stronger cash position are mildly favorable versus expectations, while negligible revenue, higher burn and no new barzolvolimab efficacy evidence limit the upside from this routine quarterly release.
Read the original 8-K on SEC EDGAR ↗